Rita Rodrigues-Lopes

Dr. Rita Rodrigues-Lopes


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 October 2023 in Journal of Shoulder and Elbow Surgery
Verified
Journal Article
Open access
RRRita Rodrigues-Lopes
Rita Rodrigues-Lopes
FSFábia Silva
Fábia Silva
JTJoão Torres
João Torres
There is still no consensus among surgeons on whether to perform a 1- or 2-stage surgical revision in infected shoulder arthroplasties. The aim of this systematic review and meta-analysis is to rigorously synthesize published studies evaluating the clinical outcomes, recurrence of infection, and other clinical complications in order to discuss which is the best strategy for treating periprosthetic joint infection after shoulder arthroplasty. Upon research using the PubMed, Scopus, and Web of Science databases, in November 2022, studies that presented 1- or 2-stage surgical revision as a treatment for periprosthetic joint infection after shoulder arthroplasty and assessed the reinfection rate on these patients, as well as other clinical outcomes, with a minimum follow-up of 12 months, were included. Study quality was evaluated using the Methodological Index for Non-Randomized Studies (MINORS) score. Reinfection and complication rates were extracted, and pooled estimates were calculated using the random-effect model. After careful screening, 44 studies were included, 5 reporting on 1-stage and 30 on 2-stage revisions and 9 assessing both strategies. A total of 185 shoulders were reported in 1-stage revision studies, whereas 526 shoulders were reported in 2-stage revision studies. The overall pooled random-effects reinfection rate was 6.68% (95% confidence interval [CI]: 3.76-10.13), with low heterogeneity (I2 = 28%, P = .03). One-stage revision showed a reinfection rate of 1.14% (95% CI: 0.00-4.88), whereas 2-stage revision analysis revealed a reinfection rate of 8.81% (95% CI: 4.96-13.33). There were significant statistical differences between 1- and 2-stage reinfection rates (P = .04). The overall pooled rate for other clinical complications was 16.76% (95% CI: 9.49-25.15), with high heterogeneity (I2 = 70%, P < .01). One-stage revision had a complication rate of 6.11% (95% CI: 1.58-12.39), whereas the 2-stage revision complication rate was 21.26% (95% CI: 11.51-32.54). This difference was statistically significant (P = .03). This is the first systematic review and meta-analysis showing significant statistical differences between 1- and 2-stage surgical revision in infected shoulder arthroplasties. Provided the right conditions exist, 1-stage revision shows better results in infection control, with lower clinical complications and possible better clinical outcomes.

30 July 2026 in Biochem
Verified
Journal Article
Open access
PDF file
ADAlexandra da Costa Duarte
Alexandra da Costa Duarte
RRRita Rodrigues-Lopes
Rita Rodrigues-Lopes
ASAna Isabel Severino
Ana Isabel Severino
MOMatilde Oliveira
Matilde Oliveira
IGInês Guerra
Inês Guerra
HRHugo Ribeiro
Hugo Ribeiro
Background/objectives: Benzodiazepines are widely prescribed as adjuvants in pain management, particularly for musculoskeletal conditions, with prescription rates for back and chronic pain more than doubling between 2003 and 2015. Yet, the evidence supporting this practice remains poorly defined. This study evaluates the efficacy of benzodiazepines in pain management, analyzing comparative data, pharmacological mechanisms, and global clinical guidelines. Methods: Narrative review informed by a predefined systematic search of PubMed, Scopus, Cochrane Library and Web of Science. We searched for direct comparative studies between diazepam, alprazolam, and lorazepam in pain management identified no eligible studies, revealing a significant evidence gap despite decades of clinical use. This absence of comparative evidence prompted a broader narrative examination of the evidence base for benzodiazepines across pain conditions. Results: The available literature consistently fails to support benzodiazepine analgesia. Across 111 chronic pain conditions, analgesic benefit has been demonstrated for only two rare conditions: burning mouth syndrome (evidence primarily for topical clonazepam) and stiff person syndrome (primarily case series and clinical experience). In low back pain, the condition most associated with benzodiazepine prescribing, recent randomized trials show no benefit or even harm compared to placebo, and the only positive pooled evidence derived from trials of tetrazepam, a drug withdrawn from the European market in 2013. In rheumatoid arthritis, pooled data from six small trials show no benefit over placebo at any time point. The pharmacological basis for this clinical failure is now well characterized: conventional non-selective benzodiazepines produce dose-limiting sedation before achieving sufficient receptor occupancy at the α2/α3 GABA-A subtypes responsible for antihyperalgesic effects. Despite the lack of demonstrated efficacy, prescribing persists, likely driven by clinical inertia and patient expectations reflecting anxiolytic rather than analgesic properties. Guidelines from the WHO, NICE, the VA/DoD, the American College of Physicians, the American Academy of Family Physicians, and the Wilderness Medical Society uniformly recommend against benzodiazepine use for pain. This convergence of absent efficacy, well-documented harm, and unanimous guideline opposition supports the conclusion that benzodiazepines should not be prescribed as analgesic adjuvants. Conclusions: Although the focused search targeted head-to-head trials, a broader narrative synthesis and prior comprehensive reviews likewise demonstrate a paucity of high-quality evidence for benzodiazepine analgesia. Future research should focus on subtype-selective GABA-A modulators and on strategies to align clinical practice with the existing evidence, including structured deprescribing interventions.

10 November 2026 in Biochem
Verified
Journal Article
Open access
PDF file
CPCarolina Damas Pereira
Carolina Damas Pereira
GSGonçalo Silva
Gonçalo Silva
BSBeatriz Pereira Clemente de Sousa
Beatriz Pereira Clemente de Sousa
CPCarolina Portela
Carolina Portela
CTCarolina Vilela Teixeira
Carolina Vilela Teixeira
HRHugo Ribeiro
Hugo Ribeiro
Background: Methocarbamol is a centrally acting skeletal muscle relaxant widely used for musculoskeletal pain associated with muscle spasm, despite an incompletely understood mechanism of action and uncertainty regarding its efficacy compared with placebo or other pharmacological interventions. Objective: To evaluate the efficacy of methocarbamol in reducing pain intensity in adults (≥18 years) with acute or chronic pain, compared with placebo or other pharmacological interventions, and to assess its impact on quality of life and other pain-related outcomes. Methods: This systematic review was conducted according to the PRISMA 2020 statement and prospectively registered in PROSPERO (CRD420261440769). PubMed, Scopus, Web of Science, and Cochrane Library were searched from inception to 30 May 2026. Randomized and non-randomized controlled trials, cohort studies, case series, and narrative or systematic reviews reporting an extractable pain-related outcome were eligible. Risk of bias was assessed using RoB 2, ROBINS-I, or the Newcastle–Ottawa Scale, and level of evidence was graded per OCEBM 2011 criteria. Given substantial clinical and methodological heterogeneity, findings were synthesized narratively. Results: Twenty-eight studies (1959–2025; n = 30–9089), comprising 9 randomized controlled trials, 14 observational studies, 4 narrative/bibliographic reviews, and 1 case series, were included, spanning acute low back pain, postoperative/perioperative pain, trauma (including rib fractures), trigeminal neuralgia, cirrhosis-related muscle cramps, muscle strain, and opiate withdrawal. Results were inconsistent across indications: some trials showed benefit when methocarbamol was combined with NSAIDs or compared with opioids, while others—including the largest cohorts—found no advantage, partly attributable to confounding by indication. Opioid-sparing effects were observed in select postoperative and trauma populations. Methodological quality was generally moderate-to-high risk of bias. Conclusions: Evidence supporting methocarbamol’s analgesic efficacy is heterogeneous and inconclusive. Benefit appears most plausible in pain syndromes driven by muscle spasm, and it may have a role within multimodal, opioid-sparing strategies in selected postoperative and trauma settings. The available evidence is insufficient to support routine use across the clinical settings evaluated. Adequately powered, standardized randomized controlled trials are needed to clarify its true effect and identify patients most likely to benefit.